Skip to content

Biohaven BHVN Total Current Liabilities

Total Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$36.63B+21.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$39.82M+24.3%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$17.9M+90.7%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$73.56M-46.4%
uniQure logo
uniQureQURE
$59.2M+63.0%
Roivant Sciences logo
Roivant SciencesROIV
$281.24M+88.2%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's total current liabilities?
Biohaven (BHVN) reported total current liabilities of $52.08M in Q1 2026.
How has Biohaven's total current liabilities changed year-over-year?
Biohaven's total current liabilities decreased by 68.3% year-over-year, from $164.03M to $52.08M.
What is the long-term trend for Biohaven's total current liabilities?
Over 4 years (2021 to 2025), Biohaven's total current liabilities has grown at a 28.9% compound annual growth rate (CAGR), from $41.94M to $115.93M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.